COQ6 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin inhibits HMG-CoA reductase, which is upstream in the biosynthesis pathway of ubiquinone (coenzyme Q). By limiting the availability of its precursors, COQ6, which is involved in the biosynthesis of coenzyme Q10, may have reduced substrate availability, leading to functional inhibition. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin also targets HMG-CoA reductase, leading to decreased synthesis of mevalonate, a precursor in the ubiquinone biosynthetic pathway. Reduced precursor levels can hinder COQ6 function which relies on these substrates to produce coenzyme Q10. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Rosuvastatin, another HMG-CoA reductase inhibitor, would similarly reduce the availability of mevalonic acid for ubiquinone production, potentially hampering the enzymatic activity of COQ6 in coenzyme Q10 synthesis. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $69.00 $162.00 $787.00 | 2 | |
Pravastatin's inhibition of HMG-CoA reductase decreases mevalonate synthesis. This action can indirectly inhibit COQ6 by limiting the availability of crucial substrates needed for coenzyme Q10 biosynthesis. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin inhibits HMG-CoA reductase, which reduces mevalonate production. Lower mevalonate levels can impede the biosynthesis pathway of coenzyme Q10, thus functionally inhibiting COQ6's role in this pathway. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Fluvastatin, by inhibiting HMG-CoA reductase, leads to reduced synthesis of mevalonate, a key building block for ubiquinone. This limits the substrates necessary for COQ6 activity in coenzyme Q10 synthesis. | ||||||
Cerivastatin, Sodium Salt | 143201-11-0 | sc-207418 | 2.5 mg | $179.00 | ||
Cerivastatin's inhibition of HMG-CoA reductase decreases the pool of mevalonate. As mevalonate is a precursor in coenzyme Q10 biosynthesis, COQ6 activity could be indirectly inhibited due to lack of substrate. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Terbinafine inhibits squalene epoxidase, another enzyme in the cholesterol biosynthesis pathway which is also required for coenzyme Q10 biosynthesis. By inhibiting upstream processes, COQ6 may be indirectly inhibited due to a reduced supply of intermediates needed for the production of coenzyme Q10. | ||||||
Zaragozic Acid A | 142561-96-4 | sc-391058 sc-391058A | 1 mg 5 mg | $225.00 $615.00 | 7 | |
Zaragozic acid A inhibits squalene synthase, an enzyme upstream of COQ6 in the coenzyme Q10 biosynthesis pathway. This inhibition could decrease the overall flow of substrate through the pathway, potentially inhibiting COQ6 activity as a result. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), which can lead to upregulation of genes involved in fatty acid oxidation and a concurrent downregulation of lipid biosynthesis pathways, potentially diminishing the availability of substrates for COQ6. | ||||||